Intellia Therapeutics NTLA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's operating income?
- Intellia Therapeutics (NTLA) reported operating income of -$100.53M in Q1 2026.
- How has Intellia Therapeutics's operating income changed year-over-year?
- Intellia Therapeutics's operating income increased by 16.8% year-over-year, from -$120.81M to -$100.53M.
- What is the long-term trend for Intellia Therapeutics's operating income?
- Over 4 years (2021 to 2025), Intellia Therapeutics's operating income has grown at a 13.3% compound annual growth rate (CAGR), from -$267.85M to -$440.99M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.